Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Warfarin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VKORC1 known ✓ | Q9BQB6 | 3/20 | 0.97 |
| ▸ | CYP2C9 | P11712 | 10/20 | 0.97 |
| ▸ | ALB | P02768 | 2/20 | 0.97 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.97 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.97 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.97 |
| ▸ | PCSK7 | Q16549 | 1/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.75 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.75 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.75 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.73 |
| ▸ | BRD4 | O60885 | 1/20 | 0.67 |
| ▸ | NQO1 | P15559 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Warfarin SCHEMBL28534047 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL5483689 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL34347 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL13278154 | 1.00 | CYP2C9 (0.97) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL29400364 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3689 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL662875 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL4439794 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL2139452 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E | |
| Warfarin SCHEMBL3792087 | 0.99 | CYP2C9 (1.00) | CYP2C9VKORC1ALBHSD17B10KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9451914-B2 | Integrated needle and test strip assembly and method of use | CHARLESTON AREA MEDICAL CENTER, INC. (US) | 2016-09-27 | — | — | US | disclosed |
| US-20130172780-A1 | Integrated Needle and Test Strip Assembly and Method of Use | CHARLESTON AREA MEDICAL CENTER, INC. (US) | 2013-07-04 | — | — | US | disclosed |
| US-5935802-A | Method of assaying a blood sample for prothrombin | EVANSTON NORTHWESTERN HEALTHCARE RESEARCH INSTITUTE (US) | 1999-08-10 | — | — | US | disclosed |
| US-5252712-A | Receptor binding assay for detecting liver disorder, vitamin deficiency | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1993-10-12 | — | — | US | disclosed |
| EP-0182495-B1 | IMMUNOASSAY MEANS AND METHODS USEFUL IN HUMAN NATIVE PROTHROMBIN AND HUMAN ABNORMAL PROTHROMBIN DETERMINATIONS | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1990-04-18 | — | — | EP | disclosed |
| US-4769320-A | Immunoassay means and methods useful in human native prothrombin and human abnormal prothorombin determinations | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1988-09-06 | — | — | US | disclosed |
| EP-0182495-A1 | Immunoassay means and methods useful in human native prothrombin and human abnormal prothrombin determinations | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 1986-05-28 | — | — | EP | disclosed |